Evidence map›Paper›PMID 23155502›Full record

ArticleIMA fungus2012

The impacts of the discontinuation of dual nomenclature of pleomorphic fungi: the trivial facts, problems, and strategies.

Uwe Braun

Abstract read
In one paragraph

Article in IMA fungus, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Uwe BraunMartin-Luther-Universität, Institut für Biologie, Bereich Geobotanik und Botanischer Garten, Herbarium, Neuwerk 21, 06099 Halle (Saale), Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symposium "One fungus = Which name" held in Amsterdam 12-13 April 2012, addressed the drastic changes in the naming of pleomorphic fungi adopted by the 18(th) International Botanical Congress in Melbourne in 2011. Possible solutions and ways to face resulting problems were suggested. The fundamental change is that under the new rules fungi in future will be treated nomenclaturally like plants and all other groups of organisms ruled by the ICN, i.e. with one correct name for each species. Numerous discussions and statements during the Symposium reflected widespread anxieties that these rules could negatively influence taxonomic work on pleomorphic fungi. However, they are groundless, being based on misunderstandings and confusion of nomenclature and taxonomy. With pleomorphic fungi, taxonomists will in future have to answer the question whether different morphs can represent one fungus (taxon), but this remains a taxonomic decision and has nothing to do with nomenclature. Furthermore, the ICN does not and cannot rule on how this decision is made. Thus it cannot provide rules based solely on methods involving morphology in vivo or in vitro, molecular analyses, physiological and biochemical data, inoculation experiments in pathogenic groups or any other methods or combinations of them. It is up to the taxonomist to select appropriate methods and to decide which data are sufficient to introduce new taxa. Some future problems and strategies around the application of anamorph- and teleomoph-typified taxon names (genera and species), are discussed here, using the recently monographed powdery mildews (Erysiphales) as an example.

Indexed as

anamorphArticle 59Erysiphalesfungifungi, and plantsInternational Code of Nomenclature for algaeteleomorph

Identifiers

PMID23155502
PMCPMC3399104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.